Baclofen tablets, a subsidiary of Qianjin Pharmaceutical (600479.SH), obtained a drug registration certificate

Zhitongcaijing · 2d ago

Zhitong Finance App News, Qianjin Pharmaceutical (600479.SH) issued an announcement. Recently, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., a subsidiary of the company, received the “Drug Registration Certificate” for baclofen tablets approved and issued by the State Drug Administration. Baclofen tablets are suitable for severe but reversible muscle spasms caused by multiple sclerosis, and may have a certain curative effect on spasms caused by infectious, degenerative, traumatic, tumors, or spinal cord diseases of unknown cause. According to Moentropy Pharmaceutical data, the total sales of baclofen tablets in the domestic medical market and retail market in 2025 was 247 million yuan.